Physician

Meghna Kumar-Pelayo, M.D.

According to 2025 Medicare claims, Meghna Kumar-Pelayo, M.D. (NPI: 1629390471) practices epileptologists in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is BAYCARE MEDICAL GROUP, INC. (NPI: 1043269871; TIN: 593140335) and primary practice location at 33705-1410. Kumar-Pelayo is affiliated with the Pearl Network, LLC (ACO ID: D0243), participating under the REACH model.

Kumar-Pelayo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 234 traditional Medicare patients, billed 726 HCPCS/CPT codes, and received $42,568 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,954 prescription claims across 284 beneficiaries totaling $256,023 in drug costs, led by Aptiom (Eslicarbazepine Acetate). 2018 DME data shows 11 claims. Open Payments data shows 116 records totaling $2,662. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $64,573 to $256,023. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	168	300	$27,625
2016	435	916	$72,814
2017	463	1,018	$83,161
2018	505	1,058	$92,435
2019	477	856	$78,412
2020	364	728	$65,910
2021	341	757	$65,204
2022	405	758	$65,073
2023	313	584	$49,522
2024	234	726	$42,568

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	112	618	$64,573
2016	113	737	$83,585
2017	139	895	$112,467
2018	158	935	$201,844
2019	181	1,193	$304,680
2020	209	1,362	$260,093
2021	236	1,634	$302,625
2022	252	1,679	$369,548
2023	267	1,859	$245,054
2024	284	1,954	$256,023

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	11	$271
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	30	30	$113
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	80	123	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	84	133	$59
95816	Measurement of brain wave activity (eeg), awake and drowsy	44	46	$42
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	129	252	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Aptiom	Eslicarbazepine Acetate	16	480	$40,062
Briviact	Brivaracetam	16	464	$21,885
Emgality Pen	Galcanezumab-Gnlm	17	506	$11,552
Levetiracetam	Levetiracetam	298	19,013	$10,006
Carbamazepine Er	Carbamazepine	35	2,020	$7,198

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	116	$2,662	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Meghna Kumar-Pelayo, M.D.?

Tedicare shows public-source Medicare data for Meghna Kumar-Pelayo, M.D. (NPI 1629390471), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Meghna Kumar-Pelayo, M.D. have ACO affiliation data?

Meghna Kumar-Pelayo, M.D. is shown with ACO affiliation data for Pearl Network, LLC (REACH, ACO ID D0243).

What billing organization is linked to Meghna Kumar-Pelayo, M.D.?

Meghna Kumar-Pelayo, M.D. is linked to BAYCARE MEDICAL GROUP, INC. (billing NPI 1043269871) in the available physician profile data.

Does Meghna Kumar-Pelayo, M.D. have Open Payments data?

Meghna Kumar-Pelayo, M.D. has 116 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.